OptimizeRx Corporation — Q3 2022 Form 10-Q
Business context and reporting period. OptimizeRx is a digital health technology company connecting life sciences organizations, healthcare providers, and patients through a point-of-care network. This unaudited quarterly report covers the three and nine months ended September 30, 2022; comparisons are with the corresponding 2021 periods.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $15.1 million | $16.1 million | $42.8 million | $41.0 million |
| Gross profit / margin | $9.4 million / 62.4% | $9.1 million / 56.3% | $26.5 million / 62.0% | $23.2 million / 56.7% |
| Operating expenses | $13.2 million | $9.0 million | $37.9 million | $23.5 million |
| Operating income (loss) | $(3.8) million | $0.04 million | $(11.4) million | $(0.3) million |
| Net income (loss) | $(3.5) million | $0.04 million | $(11.1) million | $(0.2) million |
| Basic and diluted loss per share | $(0.19) | Approximately break-even | $(0.62) | $(0.01) |
For the nine months, operating cash flow was $7.9 million, versus $2.1 million in 2021. Investing activities used $39.7 million, including $37.5 million invested in short-term U.S. Treasury bills and $2.0 million paid for the EvinceMed acquisition. Financing activities used $11.5 million, principally reflecting $12.6 million of share repurchases, partly offset by $1.1 million from option exercises. Cash and cash equivalents were $41.3 million at quarter-end; short-term investments were $37.5 million.
Current assets were $99.3 million and current liabilities $6.1 million, yielding approximately $93.2 million of working capital and a 16.2 current ratio. Total liabilities were $6.3 million, principally lease obligations; the filing reports no borrowings. Lease liabilities totaled approximately $0.25 million. The company also disclosed $15.5 million of future minimum payments under partner messaging-capacity arrangements for 2023–2025.
Material changes versus prior comparable periods
- Q3 revenue declined 6.4%, primarily because one customer brand did not renew solutions. Nine-month revenue increased 4.4%, driven by access solutions.
- Gross margin improved in both comparison periods, which management attributed to solution and channel mix, including more activity through lower-cost channels and higher-margin program-design services.
- Operating expenses rose 46% in Q3 and 61% for the nine months, reflecting workforce and technology investment and substantially higher stock-based compensation. Nine-month stock-based compensation was $11.5 million, versus $2.6 million in the prior-year statement of operations.
- Management cited macroeconomic factors and slower customer spending, particularly on large or new implementations, as contributing to elongated sales cycles. Key indicators included 96% net revenue retention versus 161%, and average revenue per top-20 pharmaceutical manufacturer of $2.19 million versus $2.52 million. Top-20 manufacturer customer penetration increased to 95% from 90%.
- The April 2022 EvinceMed asset acquisition added specialty-pharmaceutical access capabilities. The stated purchase price was approximately $12.1 million, comprising cash, shares, and amounts previously paid; $4.1 million was allocated to acquired technology and $7.9 million to goodwill. Purchase accounting remained provisional.
Outlook, risks, and unusual items
- No specific full-year revenue or earnings guidance is provided. Management expected Q4 revenue to exceed Q3, citing contracts secured or anticipated and typical pharmaceutical marketing seasonality; it expected gross margin to remain relatively constant and compensation expense to be only marginally higher than in Q3.
- Management said existing cash and operating cash generation should fund operations and planned growth for at least the next 12 months, and expected to generate cash beyond that period. It may seek financing for acquisitions, partnerships, capital expenditures, or working capital; an effective shelf registration permits securities issuance.
- The company repurchased 706,114 shares for $12.6 million through September 30 under a program authorizing up to $20 million. It reported additional purchases of 400,492 shares at a weighted average $14.75 in October through November 3.
- Risks highlighted include dependence on healthcare-industry spending and electronic prescribing/EHR partners, customer concentration, inflation and economic slowdown, competition, growth and acquisition integration, cybersecurity, and regulatory and operational risks. The company reported that its largest partner generated 53.9% of revenue in 2021.
- Management said COVID-19 had no material net financial impact in the first nine months of 2022, while uncertainty remained. The company reported no material pending litigation and no income tax expense or benefit for the period, citing net operating loss carryforwards.
- Disclosure controls were assessed as effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether Q4 revenue exceeded Q3 and whether the expected seasonality and new contracts translated into sustained growth.
- Whether customer spending and sales cycles improved, particularly among large pharmaceutical customers, and how net revenue retention evolves.
- Whether gross-margin gains persist and whether operating-cost growth, especially stock-based compensation, moderates as management expected.
- Cash generation after the Treasury purchases and repurchases, and the timing and cash impact of the $15.5 million partner commitments.
- EvinceMed integration, final purchase-price allocation, and realization of expected commercial benefits; also monitor the remaining share-repurchase authorization and dilution from equity awards.